KYPHA INC.
Point-of-care platform using multiplex quantitative lateral flow assays to measure complement system activation biomarkers
- Sector
- Medtech
- Headquarters
- SAINT LOUIS, MO
- Founded
- 2009
- Latest Form D
- $5.2M, May 2022
- Total capital
- $11.7M
- Federal grants
- $436K
- 2 awards · 2016
- Rank in peer group#456 of 542
- Private capital raised
- $11.3M
- 8 Form D · last May 2022
- 54 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 3
- 11 pending · first 2015
- Rank in peer group#60 of 542
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 8th filing$5.2M
- Private capital raisedForm D · SEC · 7th filing$950K
- Private capital raisedForm D · SEC · 6th filing$1.6M
- Federal grantHealth and Human S · Phase I · Reducing time, sample handling, and staff requirements for complement activation monitoring in clinical trials$218K
- Federal grantHealth and Human S · Phase I · Reducing time, sample handling, and staff requirements for complement activation monitoring in clinical trials$218K
- Private capital raisedForm D · SEC · 5th filing$2.1M
- Private capital raisedForm D · SEC · 4th filing$398K
- Private capital raisedForm D · SEC · 3rd filing$750K
- Private capital raisedForm D · SEC · 2nd filing$200K
- Private capital raisedForm D · SEC · 1st filing$206K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 542 peers
Line = medianMedtech · Device
- Federal grantsBelow median
- Granted patents#60 · top 11%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Paul K. OlsonResearcherDirectorLinked by 2 patents
- Chad StieningExecutive Officer, DirectorNamed in SEC Form D filings
- David K. SmollerDirectorNamed in SEC Form D filings
- James D. MarselisDirectorNamed in SEC Form D filings
- James MerselisDirectorNamed in SEC Form D filings
- Jonathan D. SackierDirectorNamed in SEC Form D filings
Show all 13 people
- Nick Scott StatenExecutive OfficerNamed in SEC Form D filings
- Peter D. ReineckeDirectorNamed in SEC Form D filings
- Peter A. TakesExecutive OfficerNamed in SEC Form D filings
- R. Charles MoyerDirectorNamed in SEC Form D filings
- Sultan MeghjiDirectorNamed in SEC Form D filings
- T. Vernon FosterDirectorNamed in SEC Form D filings
- T. Scott GloverExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 3 granted of 14- PendingTarget MeasurementUSPTOApplication 18289794
- GrantedMethods For Predicting And Treating Patients With Increased Risk Of Adverse Pregnancy OutcomeUSPTOUS 11,029,318
- GrantedLateral Flow Immunoassay For Complement Activation And Methods Of Use For Point-of-care Assessment Of Complement-associated DisordersUSPTOUS 9,939,446
Show all 14 patent records
- Target MeasurementAug 29, 2024 · Application 18289794Pending
- Methods For Predicting And Treating Patients With Increased Risk Of Adverse Pregnancy OutcomeJun 8, 2021 · US 11,029,318Granted
- Lateral Flow Immunoassay For Complement Activation And Methods Of Use For Point-of-care Assessment Of Complement-associated DisordersApr 10, 2018 · US 9,939,446Granted
- Detecting Complement ActivationMar 24, 2016 · Application 14845785Pending
- Detecting Complement ActivationOct 20, 2015 · US 9,164,088Granted
- Nanocomposites For Imaging And Drug DeliverySep 10, 2015 · Application 14430186Pending
- Nanocomposites For Imaging And Drug DeliveryApplication PCTUS2013061035Pending
- Detecting Complement ActivationApplication PCTUS2013038897Pending
- Lateral Flow Immunoassay For Complement Activation And Methods Of Use For Point-of-care Assessment Of Complement-associated DisordersApplication PCTUS2011058945Pending
- Target MeasurementApplication PCTUS2022027941Pending
- Target MeasurementApplication 63185696Pending
- Methods For Predicting Flare And Improving Treatment Of PatientsApplication PCTUS2016048874Pending
- Methods For Predicting Flare And Improving Treatment Of Lupus PatientsApplication 62236004Pending
- Methods For Predicting Flare And Improving Treatment Of Lupus PatientsApplication 62211548Pending
Related companies, and why
- Adagio MedicalSimilar federal contract value in Medtech · null in contracts
- Francis Medical, Inc.Similar federal contract value in Medtech · null in contracts
- ALLVIVO VASCULAR, INC.Similar federal contract value in Medtech · null in contracts
- Vivifi Medical LLCSimilar federal contract value in Medtech · null in contracts
- WASATCH PHOTONICS, INC.Similar federal contract value in Medtech · null in contracts
- VOLATYLIX INCSimilar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .